Baird Financial Group Inc. Lowers Holdings in Repligen Corporation $RGEN

Key Points

• Baird Financial Group Inc. has decreased its stake in Repligen Corporation by 15% and now owns 301,153 shares worth approximately $38.3 million.
• Several hedge funds, including KBC Group NV and GAMMA Investing LLC, have recently adjusted their positions in Repligen, indicating a mixed interest from institutional investors.
• Repligen reported $182.37 million in revenue for the last quarter, exceeding estimates, but reported a EPS of $0.37, missing expectations by $0.03.

Baird Financial Group Inc. cut its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 15.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 301,153 shares of the biotechnology company's stock after selling 53,084 shares during the period. Baird Financial Group Inc. owned about 0.54% of Repligen worth $38,319,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. KBC Group NV raised its position in Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock valued at $324,000 after purchasing an additional 329 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in Repligen during the 1st quarter valued at $132,000. XTX Topco Ltd raised its position in Repligen by 34.2% during the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock valued at $1,646,000 after purchasing an additional 3,295 shares in the last quarter. GAMMA Investing LLC raised its position in Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 274 shares in the last quarter. Finally, TD Asset Management Inc raised its position in shares of Repligen by 10.9% in the 1st quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company's stock worth $6,511,000 after acquiring an additional 5,014 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by insiders.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded up $4.40 during trading on Thursday, hitting $120.58. The stock had a trading volume of 841,555 shares, compared to its average volume of 774,250. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The stock has a market capitalization of $6.78 billion, a price-to-earnings ratio of -482.30, a price-to-earnings-growth ratio of 2.25 and a beta of 1.07. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock has a 50-day simple moving average of $121.58 and a two-hundred day simple moving average of $129.76.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same quarter in the previous year, the business earned $0.40 earnings per share. The company's revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Wells Fargo & Company reduced their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Evercore ISI reduced their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Stephens raised Repligen to an "overweight" rating and set a $160.00 price target for the company in a research report on Tuesday, July 22nd. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $205.00 price target on shares of Repligen in a research report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $169.55.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.